retatrutide type 2 diabetes phase 2 trial hba1c 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Eli Lilly's Retatrutide Advances Toward

I'm impressed with the results

It also offers useful information about the different types of medication or the latest research on GLP-1, based on their profile

X 21, 101209

The money-back guarantee is also a nice touch

According to the SmPC and STEP clinical trials, these include: Nausea (affecting approximately 40-45% of patients) Vomiting (approximately 15-25% of patients) Diarrhoea (affecting approximately 25-30% of users) Constipation (approximately 20-25% of patients) Abdominal pain and bloating Gastro-oesophageal reflux For individuals taking oral anti-epileptic medications , severe or persistent vomiting could theoretically reduce drug absorption, potentially affecting seizure control